This hyperlink will direct you to a non-governmental Website or application.

The appearance of external hyperlinks does not constitute endorsement by the United States Department of Health & Human Services (HHS) of the hyperlinked Website or application, or the information, products or services contained therein. Such hyperlinks are provided consistent with the intended purpose of this HHS Website. Visitors to the hyperlinked Website or application will be subject to the Website or application's privacy policies. These practices may be different than those of this HHS Website.

You will be redirected to: link

• Home
• Quick Guide to Healthy Living
• Personal Health Tools
• Health A-Z
• Health News
• Find Services & Information
• Popular Requests
• Español

• E-cards
• National Health Observances

Estrogen and Progestin Dilemma: New Advice, Labeling Guidelines

Internet URL

http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm135318.htm  

Sponsoring Agency

U.S. Food and Drug Administration

Description

The Food and Drug Administration is giving important new safety advice to postmenopausal women and their health-care providers concerning drug products that contain estrogen. The updated advice, which includes product label revisions, reflects the agency's review of data from the Women's Health Initiative (WHI) study, sponsored by the National Institutes of Health.

Related Topics